Aizpurua-Olaizola Oier, Elezgarai Izaskun, Rico-Barrio Irantzu, Zarandona Iratxe, Etxebarria Nestor, Usobiaga Aresatz
Department of Analytical Chemistry, University of the Basque Country (UPV/EHU), Barrio Sarriena s/n, 48940 Leioa, Spain.
Department of Neuroscience, University of the Basque Country (UPV/EHU), Barrio Sarriena s/n, 48940 Leioa, Spain.
Drug Discov Today. 2017 Jan;22(1):105-110. doi: 10.1016/j.drudis.2016.08.005. Epub 2016 Aug 20.
The endocannabinoid system (ECS) is involved in many physiological regulation pathways in the human body, which makes this system the target of many drugs and therapies. In this review, we highlight the latest studies regarding the role of the ECS and the drugs that target it, with a particular focus on the basis for the discovery of new cannabinoid-based drugs. In addition, we propose some key steps, such as the creation of a cannabinoid-receptor interaction matrix (CRIM) and the use of metabolomics, toward the development of improved and more specific drugs for each relevant disease.
内源性大麻素系统（ECS）参与人体许多生理调节途径，这使得该系统成为许多药物和疗法的靶点。在本综述中，我们重点介绍了关于ECS的作用以及靶向该系统的药物的最新研究，特别关注新型大麻素类药物的发现依据。此外，我们提出了一些关键步骤，例如创建大麻素受体相互作用矩阵（CRIM）和使用代谢组学，以开发针对每种相关疾病的改良型和更具特异性的药物。
